ERYTECH reports positive top-line Phase III results from clinical study with GRASPA® in Acute Lymphoblastic Leukemia

ERYTECH reports positive Phase III results from its pivotal study with GRASPA® in Acute Lymphoblastic Leukemia.

Menu